NVDA ) bestselling GeForce card, the GTX 760, and is expected to offer at least similar performance with the GeForce GTX 760, while achieving in parallel lower ..... limited to the similar performance (with GTX 760) and energy hungrier R9 280X and to
GTx (NASDAQ: GTXI ) Q2 results : Revenue: $0; Operating Expenses: $10.9M (-14.8%); Operating Loss: ($10.9M) (+14.8
GTx (NASDAQ: GTXI ): Q2 EPS of -$0.15 misses by $0.03 . Press Release Post your comment!
BCRX , BLMN , CIE , CLDT , CNK , COH , CRZO , CVC , CVS , DWRE , EMR , END , ENZY , EXH , EXLP , EXPD , FE , FUN , GLDD , GTIV , GTXI , HCLP , HCP , HEP , IART , IFF , IIVI , INFI , IT , KWK , LIN , LPX , MDU , MGM , MMP , MSI , MWW , MZOR , NILE , NNN
We are raising GTx 's fair value on recent positive Phase II trial results for Ostarine.
GTx adds a European partner.
(Reuters) - GTx Inc's experimental drug to treat muscle wasting in cancer patients became its second successive lead drug to fail late-stage trials, wiping out nearly two-thirds of the market value...
We're dropping coverage of GTx Inc GTXI to focus our resources elsewhere.
GTx Inc. GTXI reported second-quarter results that came ..... treatment for advanced prostate cancer, GTx -758, met endpoints in a Phase II study ..... Administration, and will continue to push ahead on GTx 758. In the meantime, GTx continues to
generate substantial revenue . Acapodene is GTx 's first in - house drug candidate . The ..... traction with urologists or oncologists . GTx may not have success in repartnering Ostarine ..... large potential patient population . If GTx can establish another partnership or independently